How well does Cibinqo(abrocitinib) work?

Abrocitinib tablets are Janus kinase (JAK) 1 inhibitors. They reversibly and selectively inhibit JAK1 by blocking the adenosine triphosphate (ATP) binding site, thereby affecting cellular hematopoietic function and immune cell function. Abrocitinib tablets have good therapeutic effects, which have been confirmed in clinical trials. 

Therapeutic Effects of Abrocitinib Tablets (CIBINQO) 

1. Trial Design 

In a phase 3 double-blind trial, atopic dermatitis patients who were non-responsive to topical medications or required systemic treatment (in a ratio of 2:2:2:1) were randomly assigned to receive 200 mg or 100 mg of abrocitinib tablets orally once daily, 300 mg of dupilumab subcutaneously every other week (after a loading dose of 600 mg), or placebo. All patients received topical treatment. 

2. Setting of Trial Outcomes

The primary endpoints were the Investigator Global Assessment (IGA) response and the Eczema Area and Severity Index-75 (EASI-75) response at week 12. - The key secondary endpoints were the pruritus response at week 2 and the IGA and EASI-75 responses at week 16. 

3. Trial Results

In this trial, once-daily doses of 200 mg or 100 mg of abrocitinib tablets significantly reduced the signs and symptoms of moderate-to-severe atopic dermatitis compared with placebo at weeks 12 and 16. - The 200 mg dose of abrocitinib tablets was superior to dupilumab in the pruritus response at week 2, but the 100 mg dose was not. - At week 16, there were no significant differences between abrocitinib doses and dupilumab in most other key secondary endpoint comparisons.